Incyte Corporation filed a current report on November 13, 2026, disclosing its decision not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667 in combination with bevacizumab as first-line maintenance therapy in ovarian cancer patients.

Key Highlights

  • Study cancelled: Incyte will not proceed with the Phase 3 MAESTRA-3 study of INCB123667, a selective CDK2 inhibitor, in combination with bevacizumab.
  • Indication: The study had been designed as first-line maintenance therapy for patients with ovarian cancer.
  • Expected start date dropped: The study had been expected to begin in the fourth quarter of 2026.
  • Reason given: The company attributed the decision to "the prioritization of its clinical development portfolio," according to the filing.
  • No safety or efficacy concerns: The filing states the determination "was not based on any safety or efficacy findings from the INCB123667 clinical program."
  • Guidance unchanged: The company disclosed it does not expect this determination to affect its financial guidance or its previously disclosed long-term outlook.

Incyte Halts MAESTRA-3 Development, Cites Portfolio Prioritization

Incyte Corporation (NASDAQ:INCY), headquartered in Wilmington, Delaware, reported on November 13, 2026, under Item 8.01 (Other Events) of a Form 8-K, that it has decided not to advance the planned Phase 3 MAESTRA-3 study. The study was intended to evaluate INCB123667, described in the filing as the company's selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer.

According to the filing, the trial had been expected to begin in the fourth quarter of 2026. The company disclosed that its decision stemmed from the prioritization of its clinical development portfolio, and it explicitly stated that the determination "was not based on any safety or efficacy findings from the INCB123667 clinical program." No clinical data from the INCB123667 program were cited as a factor in the decision.

The company further disclosed that it does not expect the cancellation of the MAESTRA-3 study to affect its financial guidance or its previously disclosed long-term outlook. The Form 8-K was signed by Richard Hoffman, Executive Vice President and General Counsel of Incyte Corporation.

What Was Disclosed

Incyte filed an 8-K on November 13, 2026, disclosing the cancellation of the Phase 3 MAESTRA-3 study for INCB123667 in ovarian cancer, attributing the decision to portfolio prioritization and stating no impact on financial guidance.